A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
Recruiting · NCT06322667 · Registry updated 2026-01-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Not stated | 2026-01-23 | NCT06322667 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eisai Co., Ltd. | 15 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Eisai trial site 1 | Tokyo | Japan | 1 |
| Eisai trial site 2 | Hiroshima | Japan | 1 |
| Eisai trial site 3 | Kyoto | Japan | 1 |